These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 7761669)

  • 21. [Human recombinant erythropoietin in the treatment of myelodysplastic syndromes anemia. Meta-analytic study].
    Rodríguez JN; Diéguez JC; Muñiz R; Martino ML; Fernández-Jurado A; Amian A; Cañavate M; Prados D
    Sangre (Barc); 1994 Dec; 39(6):435-9. PubMed ID: 7855695
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effect of erythropoietin (rHuEPO) on trace elements and quality of life (Qol) in chronic hemodialysis patients.
    Hosokawa S; Yoshida O
    Int J Clin Pharmacol Ther; 1994 Aug; 32(8):415-21. PubMed ID: 7981926
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Recombinant human erythropoietin (rhEPO) treatment potentiates growth hormone (GH) response to growth hormone releasing hormone (GHRH) stimulation in hemodialysis patients.
    Cremagnani L; Cantalamessa L; Orsatti A; Vigna L; Vallino F; Buccianti G
    Clin Nephrol; 1993 May; 39(5):282-6. PubMed ID: 8513607
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Influence of erythropoietin treatment on endocrine abnormalities in haemodialyzed patients.
    Kokot F; Wiecek A; Grzeszczak W; Klepacka J; Klin M; Lao M
    Contrib Nephrol; 1989; 76():257-70; discussion 270-2. PubMed ID: 2582782
    [No Abstract]   [Full Text] [Related]  

  • 25. Erythropoietin treatment for non-uremic patients: a personal view.
    Biesma DH
    Neth J Med; 1999 Jan; 54(1):10-5. PubMed ID: 10048290
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Improvement of the quality of life for hemodialysis patients using recombinant human erythropoietin].
    Schaefer RM
    Krankenpfl J; 1988; 26(7-8):317-20. PubMed ID: 3419139
    [No Abstract]   [Full Text] [Related]  

  • 27. [A multicenter trial of Recormon within the framework of international controlled research].
    Tareeva IE; Nikolaev AIu; Klepikov PV; Lashutin SV; Riabov SI; Shostka GD; Ermolenko VM; Rozental' RL; Vorob'ev PA; Miagkov AV
    Ter Arkh; 1992; 64(8):59-62. PubMed ID: 1440400
    [No Abstract]   [Full Text] [Related]  

  • 28. How erythropoietin affects bone marrow of uremic patients.
    Sikole A; Stojanovic A; Polenakovic M; Petrusevska G; Sadikario S; Saso R; Jovanovski M
    Am J Nephrol; 1997; 17(2):128-36. PubMed ID: 9096443
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Vascular changes in hemodialysis patients in response to recombinant human erythropoietin.
    London GM; Zins B; Pannier B; Naret C; Berthelot JM; Jacquot C; Safar M; Drueke TB
    Kidney Int; 1989 Nov; 36(5):878-82. PubMed ID: 2615194
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Platelet aggregation during the recombinant human erythropoietin (rHuEPO) treatment of patients with uremia].
    Mazerska M; Pawlak K; Azzadin A; Małyszko J; Małyszko J; Myśliwiec M; Buczko W
    Pol Arch Med Wewn; 1992 Oct; 88(4):230-7. PubMed ID: 1488323
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Higher dose of erythropoietin for anemia correction in balkan endemic nephropathy patients].
    Lukić L; Mitrović D; Kovačević S; Stanišić M; Pelemiš S
    Srp Arh Celok Lek; 2012; 140(7-8):456-61. PubMed ID: 23092030
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Future trends and issues in erythropoietin. Part II.
    Stevenson KD
    Nephrol News Issues; 1992 Jun; 6(6):28, 30-1. PubMed ID: 1608477
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Influence of therapy with recombinant erythropoietin on serum levels of neopterin in hemodialyzed subjects.
    Buemi M; Allegra A; Aloisi C; Frisina N
    Am J Nephrol; 1991; 11(4):281-3. PubMed ID: 1799185
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Improvement of brain function in hemodialysis patients treated with erythropoietin.
    Grimm G; Stockenhuber F; Schneeweiss B; Madl C; Zeitlhofer J; Schneider B
    Kidney Int; 1990 Sep; 38(3):480-6. PubMed ID: 2232491
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effects of angiotensin-converting enzyme inhibitors on the treatment of anemia with erythropoietin.
    Hayashi K; Hasegawa K; Kobayashi S
    Kidney Int; 2001 Nov; 60(5):1910-6. PubMed ID: 11703610
    [TBL] [Abstract][Full Text] [Related]  

  • 36. rhEPO treatment of anemia in uremic patients.
    Bommer J; Barth HP; Schwöbel B
    Contrib Nephrol; 1990; 87():59-67. PubMed ID: 2093542
    [No Abstract]   [Full Text] [Related]  

  • 37. Hemocompatibility in hemodialysis and erythropoietin therapy.
    Opatrný K; Vít L; Opatrná S; Polakovic V; Sefrna F; Sulková S; Opatrný K
    Artif Organs; 1995 Aug; 19(8):814-20. PubMed ID: 8573001
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Stable renal function and benign course in azotemic diabetics treated with erythropoietin for one year.
    Brown CD; Friedman EA
    Contrib Nephrol; 1991; 88():182-9; discussion 190-1. PubMed ID: 2040181
    [No Abstract]   [Full Text] [Related]  

  • 39. Subcutaneous low doses of recombinant human erythropoietin in predialysis patients do not interfere with the progression of renal failure.
    Savica V; Costantino G; Monardo P; Bellinghieri G
    Am J Nephrol; 1995; 15(1):10-4. PubMed ID: 7872358
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Efficiency of once-weekly subcutaneous administration of recombinant human erythropoietin versus three times a week administration in hemodialysis patients.
    Lago M; Pérez-García R; García de Vinuesa MS; Anaya F; Valderrábano F
    Nephron; 1996; 72(4):723-4. PubMed ID: 8730458
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.